Inactive Instrument

Acacia Pharma Group plc

Equities

ACPH

GB00BYWF9Y76

Acacia Pharma Group plc Reports Earnings Results for the Half Year Ended June 30, 2021

September 30, 2021 at 01:22 am

Acacia Pharma Group plc announced earnings results for the half year ended June 30, 2021. For the half year, the company announced sales was USD 441,000. Operating loss was USD 24.962 million compared to USD 12.777 million a year ago. Net loss was USD 27.313 million compared to USD 15.196 million a year ago.

Latest news about Acacia Pharma Group plc

Eagle Pharmaceuticals Completes Acacia Pharma Acquisition	22-06-09	MT
Acacia Pharma's Acquisition by Eagle Pharmaceuticals Closes; Shares Delist	22-06-09	MT
Acacia Pharma Group plc(ENXTBR:ACPH) dropped from Next Biotech Index	22-06-08	CI
Acacia Pharma's Acquisition by Eagle Pharmaceuticals Nears Completion	22-06-07	MT
Eagle Pharmaceuticals, Inc. completed the acquisition of Acacia Pharma Group plc from a group of shareholders.	22-06-05	CI
Acacia Pharma Group plc Auditor Raises 'Going Concern' Doubt	22-04-28	CI
Acacia Pharma Group plc Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-28	CI
Sector Update: Health Care Stocks Posting Modest Gains Monday	22-03-28	MT
Health Care Up on Revival of Demand for Growth Sectors -- Health Care Roundup	22-03-28	DJ
Sector Update: Health Care Stocks Still Looking for Monday Direction	22-03-28	MT
Sector Update: Health Care	22-03-28	MT
FTSE 100 Closes Lower Despite Earlier Hopes on Russia, Ukraine Talks	22-03-28	DJ
FTSE 100 Rises, 10Y Gilt Yields Hit Six-Year High as Interest-Rate Rises Loom	22-03-28	DJ
FTSE Rises, Rolls-Royce Slides as Takeover Talk Remains Unconfirmed	22-03-28	DJ
FTSE 100 Rises on Optimism Over Russia-Ukraine Talks	22-03-28	DJ
Eagle Pharmaceuticals to Acquire Acacia Pharma	22-03-28	MT
Sterling Weakens Vs In-Favor Dollar, Could Drop Toward $1.30	22-03-28	DJ
Acacia Pharma Accepts $104 Million Takeover Bid from US-Based Eagle Pharmaceuticals	22-03-28	MT
Eagle Pharmaceuticals, Inc. entered into an agreement to acquire Acacia Pharma Group plc from a group of shareholders for €89.8 million.	22-03-27	CI
Acacia Pharma CFO To Step Down	22-03-23	MT
Gary Gemignani to Leave Acacia Pharma Group plc as Chief Financial Officer	22-03-23	CI
Acacia Pharma Completes US FDA's Required Study for Post-Operative Drug With No Adverse Events	21-12-13	MT
Acacia Pharma Completes Required Barhemsys Clinical Trial	21-12-13	DJ
Acacia Pharma Announces Successful Completion of Barhemsys® Post-Approval Requirement Study in Patients with Severe Renal Impairment	21-12-13	CI
ANALYST RECOMMENDATIONS : Acceleron Pharma, General Mills, Southwest Airlines, Home Depot, Wizz Air...	21-10-01

Chart Acacia Pharma Group plc

Duration

Period

More charts

Company Profile

Acacia Pharma Group plc specializes in the research and development of supportive care medicines. The products are intended to support the side effects of anti-cancer treatments (including nausea and vomiting drugs). At the end of 2021, the group had a portfolio of 3 products, including 1 in phase II of clinical development (APD403; treatment of chemically induced nausea and vomiting) and 2 in pre-launch phase: BARHEMSYS (treatment of nausea and postoperative vomiting) and BYFAVO (benzodiazepine sedative for use in invasive medical procedures in adults, such as colonoscopy and bronchoscopy).

Sector

More about the company